Monte Rosa Therapeutics, Inc. (GLUE) vs Gyre Therapeutics, Inc. (GYRE)
A side-by-side comparison of Monte Rosa Therapeutics, Inc. and Gyre Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLUE
Monte Rosa Therapeutics, Inc.
$10.02HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
GYRE
Gyre Therapeutics, Inc.
$7.11HealthcareDelayed quote: Oct 6, 2026, 12:38 PM EDT
Total return — GLUE vs GYRE
growth of $100 · dividends reinvested · last 5yGLUE -51.5% (-13.5%/yr)GYRE -16.0% (-3.4%/yr)GYRE compounded faster over this window
GLUE GYRE
GLUE vs GYRE: by the numbers
- •GLUE is the larger company ($846M vs $793M market cap).
- •Both run net losses; GYRE's is the smaller (-14.52% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | GLUE | GYRE |
|---|---|---|
| P/S ratio | 29.47 | 6.64 |
| P/B ratio | 1.74 | 7.34 |
Profitability
| Metric | GLUE | GYRE |
|---|---|---|
| Gross margin | 92.94% | 94.30% |
| Operating margin | -43.83% | 9.86% |
| Net margin | -560.85% | -14.52% |
| ROE | -33.06% | -13.30% |
| ROIC | -28.69% | -9.77% |
Growth (annualized)
| Metric | GLUE | GYRE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 84.92% |
| Total return CAGR (5Y) | -12.32% | -0.34% |
Frequently asked
- How have GLUE and GYRE total returns compared?
- Over the past 5 years, GLUE delivered -12.32% and GYRE delivered -0.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Monte Rosa Therapeutics ROEGyre Therapeutics ROEMonte Rosa Therapeutics operating marginGyre Therapeutics operating marginMonte Rosa Therapeutics revenue growthGyre Therapeutics revenue growthMonte Rosa Therapeutics free cash flowGyre Therapeutics free cash flow
Monte Rosa Therapeutics & Gyre Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.